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Summary 
 
Dysregulated mammalian TOR (mTOR) promotes cancer, but underlying 
mechanisms are poorly understood. We describe an mTOR-driven mouse 
model that displays hepatosteatosis progressing to hepatocellular carcinoma 
(HCC). Longitudinal proteomic, lipidomic and metabolomic analyses revealed 
that hepatic mTORC2 promotes de novo fatty acid and lipid synthesis leading 
to steatosis and tumor development. In particular, mTORC2 stimulated 
sphingolipid (glucosylceramide) and glycerophospholipid (cardiolipin) 
synthesis. Inhibition of fatty acid or sphingolipid synthesis prevented tumor 
development, indicating a causal effect in tumorigenesis. Increased levels of 
cardiolipin were associated with tubular mitochondria and enhanced oxidative 
phosphorylation. Furthermore, increased lipogenesis correlated with elevated 
mTORC2 activity and HCC in human patients. Thus, mTORC2 promotes 
cancer via formation of lipids essential for growth and energy production. 
 
Significance 
 
mTOR signaling is activated in most tumors, yet the molecular mechanisms 
by which mTOR drives tumorigenesis are poorly understood. In a mouse 
model that develops hepatosteatosis and liver cancer, we find that mTORC2 
promotes fatty acid, sphingolipid and glycerophospholipid synthesis, and 
thereby tumorigenesis. Thus, our study examines in unprecedented depth 
the role of mTORC2 and lipogenesis in tumorigenesis. Our findings 
demonstrate a role for mTORC2 in lipid-mediated oncogenesis that could be 
exploited for targeted cancer therapies. 
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Introduction 
 
Cancer is a disorder characterized by increased metabolic activity leading to 
enhanced cell growth and proliferation. Thus, cancer cells exhibit metabolic 
features that are distinct from non-cancerous cells (Hanahan and Weinberg, 
2011; Pavlova and Thompson, 2016). One such feature is elevated fatty acid 
(FA) synthesis; non-cancerous cells rely on exogenous sources (Schulze and 
Harris, 2012). Various enzymes that mediate FA and lipid synthesis are 
transcriptionally up-regulated in tumors (Menendez and Lupu, 2007). 
Although clinical trials for lipogenesis inhibitors are ongoing (Beloribi-Djefaflia 
et al., 2016), the regulation and function of lipids in tumors remain elusive. 
Liver cancer is the fifth most common cancer worldwide and has poor 
prognosis (Llovet et al., 2016). One risk factor for liver cancer is Non-
Alcoholic Fatty Liver Disease (NAFLD). NAFLD is characterized in part by 
excessive accumulation of triglycerides (TG) in hepatocytes (also known as 
hepatosteatosis), due to enhanced hepatic de novo FA synthesis (Lambert et 
al., 2014). NAFLD may progress to Non-Alcoholic Steatohepatitis (NASH) 
and ultimately hepatocellular carcinoma (HCC) (Postic and Girard, 2008). 
FA synthesis is induced by growth factors, through the transcription 
factor SREBP1c. Upon growth factor stimulation, precursor SREBP1c is 
proteolytically processed to yield mature Sterol Regulatory Element-Binding 
Protein-1c (SREBP1c) which is translocated into the nucleus to activate 
expression of the FA biosynthesis genes Acaca, Fasn, Scd (Horton et al., 
2002). Tumors frequently exhibit activated SREBP1c (Li et al., 2016; Ricoult 
et al., 2015). 
FAs are assembled from acetyl groups derived mainly from citrate. 
Citrate produced by the TCA cycle in mitochondria is shuttled to the 
cytoplasm and converted, by ATP-Citrate Lyase (ACLY), to acetyl-CoA and 
oxaloacetate. Oxaloacetate is converted to pyruvate, generating NADPH that 
provides reducing power for lipid synthesis. Acetyl-CoA is converted to 
malonyl-CoA by Acetyl-CoA Carboxylase (ACC). Fatty Acid Synthase 
(FASN) then condenses acetyl-CoA and several molecules of malonyl-CoA 
to produce palmitate (16 carbon unit). Stearoyl-CoA Desaturase (SCD) 
desaturates palmitate thereby generating monounsaturated FAs (MUFAs). 
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Other desaturases (FADS) generate highly polyunsaturated FAs (PUFAs). 
FAs can be stored in the form of TG. Alternatively, FAs are utilized for the 
synthesis of sphingolipids (SLs) and glycerophospholipids (GPLs) that are 
ultimately used as signaling molecules or membrane building blocks. 
The evolutionarily conserved Ser/Thr kinase Target of Rapamycin (TOR) 
controls metabolic pathways that mediate cell growth. TOR forms two 
structurally and functionally distinct protein complexes termed TOR Complex 
1 (TORC1) and TORC2 (Loewith et al., 2002). Mammalian TORC1 
(mTORC1) is activated by nutrients, growth factors and cellular energy 
(Laplante and Sabatini, 2012; Shimobayashi and Hall, 2016). Growth factors 
stimulate mTORC1 via PI3K-PDK1-AKT signaling that inhibits the negative 
regulator and tumor suppressor TSC complex, consisting of TSC1 and TSC2 
(Dibble and Cantley, 2015). The tumor suppressor PTEN negatively 
regulates both mTORC1 and mTORC2 signaling. mTORC1 directly or 
indirectly phosphorylates S6K, ribosomal protein S6, CAD, and ULK among 
others. Growth factors activate mTORC2 which phosphorylates several 
members of the AGC kinase family, including AKT at Ser473 (AKT-pSer473), 
to control various cellular processes (Sarbassov et al., 2006). mTORC2 
physiologically controls hepatic FA synthesis via AKT and SREBP1c 
(Hagiwara et al., 2012; Yuan et al., 2012). mTORC2 is also tumorigenic 
(Guertin et al., 2009; Guri and Hall, 2016), but little is known about the 
underlying mechanism(s).  
 
Results 
 
Liver specific activation of mTOR signaling promotes FA synthesis, 
hepatosteatosis, and HCC. 
To study the role of mTOR signaling in cancer, we generated mice lacking 
Tsc1 and Pten specifically in the liver (termed L-dKO mice). The L-dKO 
(Tsc1loxP/loxP; PtenloxP/loxP; Alb-Cre) mice exhibited reduced expression of 
TSC1 and PTEN in the liver, and concomitant activation of mTORC1 and 
mTORC2 signaling, as compared to age-matched littermate control mice 
(Tsc1loxP/loxP; PtenloxP/loxP) (Figure 1A). The L-dKO mice displayed 
disproportionately increased liver weight (hepatomegaly), starting at 4 weeks 
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of age (Figure S1A-C). L-dKO mice also exhibited increased serum levels of 
liver damage markers ALT, AST and LDH (Figure S1D), and elevated hepatic 
expression of cancer-associated genes Afp and Aldh (Figure S1E). L-dKO 
mice invariably presented liver cancer, detected microscopically at ~ 12 
weeks of age, and died at ~20 weeks of age at which time the liver was 
replete with tumors (Figure S1A). Histopathological analysis confirmed liver 
cancer, HCC and rarely (~10%) cholangiocarcinoma (Figures 1B, S1F).  A 
fibrotic rim, indicative of NASH, demarcated the tumors (Figure 1B). BrdU 
incorporation confirmed increased hepatocytes proliferation in tumors (Figure 
S1G). Collectively, and consistent with previous studies (Kenerson et al., 
2013), the above results indicate that dysregulated hepatic mTOR causes 
liver cancer. 
To identify early, mTOR-dependent events that promote liver cancer 
development, we performed longitudinal, unbiased quantitative proteomics 
and phosphoproteomics on liver samples from 4, 8 and 12 week-old L-dKO 
mice and littermate control mice. Pathway enrichment analysis of proteins 
and phosphorylation events that were consistently and significantly (>2 fold) 
up- or down-regulated at all three ages revealed enrichment of FA and lipid 
synthesis pathways (Figure S1H-K). Importantly, FA and lipid synthesis 
pathways were up-regulated specifically in livers developing HCC, i.e., livers 
from L-dKO mice (Figure 1C; Tables S1 and S2). Immunoblot analyses 
confirmed increased expression of FA biosynthetic enzymes in liver lysates 
from L-dKO mice (Figure 1A). Immunoblotting also showed increased levels 
of mature SREBP1c (Figure 1A), while qPCR analysis revealed increased 
expression of the Acaca, Fasn, and Scd genes (Figure S1L), indicating that 
the increase in expression of FA synthesis enzymes was at the 
transcriptional level. Hepatic expression of CD36, a long-chain fatty acid 
transporter that contributes to hepatosteatosis (Steneberg et al., 2015), was 
increased in L-dKO mice (Figures 1A, S1L), suggesting enhanced FA uptake 
in addition to synthesis. Hepatic expression of genes involved in lipid 
secretion (Apob, Mttp) or degradation (Atgl, Acox1, Mcad) was unchanged 
(Figure S1M). ACLY phosphorylation at serine 455 was increased in livers of 
L-dKO mice, as determined by phosphoproteomics and confirmed by 
immunoblotting (Figure 1A, C). ACLY phosphorylation correlated with 
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lipogenesis (Das et al., 2015). Up-regulation of lipid (in addition to FA) 
synthesis pathways was also confirmed, as described further below. 
Resected HCCs from 20 week-old L-dKO mice (12 tumors, n=4 mice) 
displayed increased expression of FA and lipid synthesis pathways, as 
determined by proteomic and transcriptomic analyses and confirmed by 
immunoblotting and immunohistochemistry (Figure 1A-C). We note that in 
experiments in which we used liver samples from 20 week-old mice, the 
samples were excised tumors (HCCs), whereas samples from younger mice 
(4, 8, 12 and 16 weeks) were whole liver. 
We next investigated FA accumulation (hepatosteatosis) and its 
correlation with tumorigenesis. Macroscopically, livers from L-dKO mice 
appeared fatty starting at 8 weeks of age. Lipid droplet specific Oil-red-O 
(ORO) staining confirmed hepatosteatosis (Figure 1D). H&E staining 
revealed enlarged hepatocytes, beginning at 8 weeks of age, likely due to a 
combination of lipid droplet accumulation and mTOR-driven cell growth 
(Figure S1N, S1O). Consistent with enhanced lipid droplet accumulation, 
hepatic TG levels were increased in L-dKO mice (Figure 1E). Hepatic TG 
accumulation was more pronounced in ad-libitum fed mice compared to mice 
starved overnight (Figure S1P). We note that all subsequent experiments 
were performed with ad-libitum fed mice. In addition to increased hepatic TG 
levels, L-dKO mice exhibited key clinical pathologies of NASH (inflamed 
hepatosteatosis), including hepatocyte ballooning, Mallory-Denk bodies, 
glycogenated nuclei, lobular inflammation and increased IL-6 (STAT3-
pTyr705) and TNF signaling, starting at 8 weeks of age (Figures S1Q-S). 
Hepatic immune cell infiltration was further confirmed by FACS analyses 
(Figure S1T). The above observations indicate that hepatosteatosis and 
NASH precedes HCC in L-dKO mice, as observed clinically. 
To investigate the effect of activated hepatic mTOR signaling and 
hepatosteatosis on whole-body metabolism, we performed indirect 
calorimetry. The respiratory exchange ratio (RER) was lower in L-dKO, 
compared to littermate control mice, despite little-to-no difference in feeding 
behavior or physical activity, suggesting that L-dKO mice are more reliant on 
FA oxidation for energy production (Figure S1U-W). L-dKO mice were 
unaltered in total fat or lean mass compared to controls, as determined by 
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longitudinal whole-body fat composition analyses (EchoMRI) (Figure S1X). 
Since L-dKO mice displayed hepatosteatosis and hepatomegaly but did not 
exhibit an overall increase in fat or lean mass, we investigated whether L-
dKO mice exhibit cancer cachexia (wasting syndrome) that may offset 
increased liver mass. Cachexia is characterized by substantial tissue loss, in 
particular of skeletal muscle (sarcopenia) and adipose tissue. Indeed, L-dKO 
mice exhibited sarcopenia and reduced adipose tissue mass (Figure S1Y-Z). 
Thus, L-dKO mice exhibit whole-body cachexia-like effects, as observed in 
hepatosteatosis patients (Lee et al., 2015). 
 
FA synthesis is required for tumor development. 
To determine whether FA synthesis is required for tumor development, 6 to 8 
week-old L-dKO and littermate control mice were treated with the FASN 
inhibitor orlistat (Sounni et al., 2014) or drug vehicle alone daily for 12 weeks. 
Orlistat-treated L-dKO mice displayed significantly fewer hepatic lipid droplets 
and liver tumors, and exhibited reduced serum liver damage markers ALT, 
AST and LDH, compared to L-dKO mice treated with drug vehicle alone 
(Figures 2A-B, S2A-C). Orlistat treatment did not reduce total liver or body 
weight (Figure S2D).  Furthermore, orlistat treatment had no effect on AKT-
pSer473 and S6-pSer235/6 (Figure S2E), indicating that drug action was not 
via inhibition of mTOR. Thus, FA synthesis is required for tumor development. 
Orlistat inhibits pancreatic lipase in addition to systemic FASN. To 
determine whether FA synthesis specifically in the liver is required for tumor 
development, we used adenovirus associated virus (AAV) to knockdown 
FASN in hepatocytes. Importantly, to achieve hepatocyte specific knockdown, 
we used an AAV with high liver tropism (AAV-DJ) and expressing shFASN 
from the albumin promoter (AAV-DJ-Albumin-shFASN-RFP, referred to as 
AAV-shFASN) (Figure S2F). AAV-shFASN or the control virus AAV-shScrmbl 
(AAV-DJ-Albumin-shScrmbl-RFP) was injected into the tail-vein of 6 to 8 
week-old L-dKO and control mice. Tumor burden was assessed in mice 
sacrificed at 20 weeks of age. FASN knockdown was confirmed by 
immunoblotting, qPCR and immunofluorescence (IF) (Figure S2G-I). L-dKO 
mice infected with AAV-shFASN exhibited significantly reduced hepatocyte 
proliferation, tumor burden and serum liver damage markers (ALT, AST and 
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LDH), compared to L-dKO mice treated with AAV-shScrmbl (Figures 2C-F 
and S2I, J). Although AAV-shFASN was very specific, it did not infect the 
whole liver, and it is likely that the few tumors that emerged arose from 
‘evaders’. Importantly, AAV-shFASN did not have a detrimental effect in wild-
type mice (not shown), indicating that in contrast to transformed hepatocytes, 
normal hepatocytes are not dependent on high levels of FASN expression. 
Wild-type mice lacking tumors presumably obtain sufficient FAs from the diet. 
Collectively, these data indicate that hepatic FA synthesis supports tumor 
development in mTOR-driven HCC. 
 
mTOR promotes de novo sphingolipid synthesis: Glucosylceramide. 
The transcriptomic and proteomic analyses described above suggested that 
mTOR promotes lipid synthesis in addition to FA synthesis. In particular, 
enzymes mediating sphingolipid (SL) and glycerophospholipid (GPL) 
synthesis were up-regulated in the liver of young L-dKO mice (4, 8, or 12 
weeks) and in tumors of 20 week-old L-dKO mice (Figure 1C). 
The rate-limiting reaction in de novo SL biosynthesis is the condensation 
of serine and palmitate catalyzed by Serine Palmitoyltransferase (SPT) to 
generate 3-keto-sphinganine (3kSN) (Aguilera-Romero et al., 2014) (Figure 
1C). 3kSN is then reduced to yield the long chain base (LCB) sphinganine 
(Sa). LCB is N-acylated, with fatty acid chains of different lengths, by CerS to 
produce dihydroceramide (DHCer). The FAs used for sphingolipid synthesis 
are produced by the FA elongases (ELOV1-7). Dihydroceramide Desaturase 
(DES1-2) adds a double bond to complete the synthesis of ceramide. 
Ceramide undergoes head group modifications in the Golgi compartment to 
yield sphingomyelin (SM) or glucosylceramide (GlcCer). GlcCer synthesis is 
catalyzed by GCS (Ugcg) that transfers glucose from uridine diphosphate 
(UDP) glucose to ceramide. Ceramide can also be converted to sphingosine 
(So) by ceramidases. SL biosynthetic enzymes, including SPT and Ceramide 
Synthase (CerS1-6), are implicated in NAFLD (Pagadala et al., 2012) and 
cancer (Ogretmen and Hannun, 2004). L-dKO mice exhibited increased 
expression (mRNA and protein) of sphingolipid anabolic enzymes, in 
particular SPT, ELOV (1, 4, 6 and 7), CerS (2, 3, 5 and 6), DES1 and 2, and 
GCS (Figure 1C). Expression of enzymes that mediate the reverse, catabolic 
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steps was not altered, with the exception of nSMase and GBA that were 
increased and decreased, respectively. Importantly, these changes 
collectively favor GlcCer synthesis. Sphingosine Kinase 1 (SPHK1) and 
Sphingosine Lyase 1 (SGPL1) that mediate sphingosine 1 phosphate (S1P) 
metabolism downstream of ceramide were also up-regulated (see 
Discussion). Altered expression of SPT (Sptlc1), Glucosylceramide Synthase 
(GCS, Ugcg), Sphingomyelin Phosphodiesterases (Smpd3 and Smpd1), and 
Sphk1 was confirmed by immunoblotting, qPCR or IF (Figures 1A, 3A and 
S3A, B). These findings suggest that de novo SL synthesis is increased in 
hepatocytes from L-dKO mice, likely leading to GlcCer accumulation. 
To determine whether the above changes in expression lead to changes 
in lipid accumulation, we performed longitudinal unbiased quantitative 
lipidomic analyses on liver samples from L-dKO mice and age-matched 
littermates. Lipid enrichment analyses revealed that L-dKO mice exhibit 
enhanced accumulation of DHCer, ceramide, and GlcCer (Figures 3B and 
S3C-D; Table S3). As suggested by the above transcriptomic and proteomic 
analyses, GlcCer displayed the most pronounced accumulation. The 
observed GlcCer accumulation in L-dKO mice was validated by IF analysis 
(Figure S3E). Thus, livers of L-dKO mice accumulate sphingolipids, with 
particularly high levels of GlcCer. 
To confirm that de novo SL synthesis, as opposed to SL salvage 
pathways that can also produce elevated levels of GlcCer, was high in L-dKO 
mice, we performed longitudinal metabolomic analyses on liver samples from 
L-dKO mice and control littermates. Indeed, sphinganine (Sa), an 
intermediate in de novo SL synthesis, was increased in L-dKO mice (Figure 
3C). Moreover, metabolomic analyses indicated that the level of the amino 
acid serine, which is required for the first step in de novo SL synthesis, was 
consistently reduced in liver samples from L-dKO mice. Alanine levels were 
not similarly depleted (Figure S3F), suggesting that the reduction in serine is 
due to consumption by de novo SL synthesis. Thus, along with the observed 
increase in fatty acid synthesis, L-dKO mice display increased hepatic de 
novo SL synthesis. 
 
Sphingolipid (GlcCer) is required for liver tumor development. 
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To determine whether the observed increase in de novo SL synthesis is 
required for tumor development, 8 week-old L-dKO and littermate control 
mice were treated with the SPT inhibitor myriocin. Myriocin or drug vehicle 
alone was administered every other day, for 12 weeks. Myriocin treatment 
reduced tumor burden and improved liver function in L-dKO mice (Figures 4A 
and S4A-B). Lipidomic analyses of tumors from L-dKO mice and of whole 
liver lysates from control mice confirmed the effect of myriocin (Figure 4B and 
Table S4).  Principal component and lipidomic analyses indicated that 
myriocin-treated L-dKO mice became more control-like (Figures 4C). 
Myriocin had no effect on AKT-pSer473 and S6-pSer235/6 (Figure S4C), 
suggesting that myriocin acted independently of mTOR signaling. Myriocin 
treatment also reduced proliferation, as assessed by PCNA expression 
(Figure S4C). Liver and body weights of myriocin-treated mice were 
unchanged (Figure S4D). Notably, expression of SPT, the rate-limiting 
enzyme in SL synthesis, is elevated in many human tumors (Figure 4D). 
Thus, de novo SL synthesis supports tumor growth. 
The above proteomic and lipidomic analyses indicated that L-dKO mice 
preferentially accumulate GlcCer (Figures 1C and 3B). Furthermore, 
expression of the GlcCer synthesis enzyme GCS correlates with 
tumorigenicity (Liu et al., 2013) and a GCS inhibitor blocked proliferation in 
various cancer cell lines (Huang et al., 2011; Wang et al., 2015). To 
determine whether GlcCer accumulation or synthesis is important for tumor 
development in vivo, we knocked down GCS in hepatocytes in L-dKO mice. 
AAV-shGCS (AAV-DJ-Albumin-shGCS-RFP) or the control virus AAV-
shScrmbl was injected into tail-vein of 6 to 8 week-old L-dKO and control 
mice. Hepatic GCS knockdown was confirmed (Figure S2K). Strikingly, 
chronic GCS inhibition significantly reduced hepatocyte proliferation, tumor 
burden and serum liver damage markers, as assayed at 20 weeks of age 
(Figure 2C-F). Thus, GlcCer synthesis is required for tumor development. 
 
mTOR promotes glycerophospholipid synthesis: Cardiolipin. 
The transcriptomic and proteomic analyses described above also suggested 
that mTOR promotes glycerophospholipid (GPL) synthesis (Figure 1C). GPL 
synthesis begins with the acylation of glycerol 3-phosphate by GPAT to 
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generate lysophosphatidic acid (LPA). LPA is then converted to phosphatidic 
acid (PA) by AGPAT. PA is converted to diacylglyceride (DAG), by the PAP 
family of enzymes. In the ‘Kennedy pathway’, DAG and choline or 
ethanolamine are condensed to yield phosphatidylcholine (PC) or 
phosphatidylethanolamine (PE), respectively (Gibellini and Smith, 2010). 
Alternatively, DAG is conjugated to CDP by CDP-DAG Synthase (CDS) to 
produce the liponucleotide CDP-DAG. CDP-DAG is used for the synthesis of 
phosphatidylinositol, phosphatidylserine, and cardiolipin (CL). CLs are 
synthesized exclusively in mitochondria (Schlame et al., 2000). 
Phosphatidylglycerophosphate Synthase 1 (PGPS1) catalyzes the rate-
limiting step in CL synthesis, condensing DAG and glycerol-3-phosphate to 
produce phosphatidylglycerolphosphate (PGP). PGP is dephosphorylated by 
the PTEN-like mitochondrial phosphatase PTPMT1, generating 
phosphatidylglycerol (PG) (Zhang et al., 2011). Cardiolipin Synthase 1 
(CLS1) attaches PG to DAG, producing immature CL that is then remodeled 
in a series of reactions. 
The transcriptomic and proteomic analyses described above and 
immunoblotting revealed increased hepatic expression of the GPL synthesis 
enzymes GPAT, AGPAT, LIPIN, CDS, PGPS1, CLS1 and PTPMT1 in L-dKO 
mice (Figures 1C, 5A), suggesting increased synthesis of GPLs, cardiolipin in 
particular. Indeed, lipidomic analysis revealed elevated levels of the GPLs 
phosphatidylinositol (PI), lysophosphatidylcholine (lysoPC) and CL, with 
accumulation of CL(18:≤1) being the most pronounced (Figure 3B).  
Importantly, the levels of PC and PE, both products of the Kennedy pathway, 
were reduced (Figure S3C). This suggests that CL is preferentially 
synthesized in L-dKO mice. Thus, again consistent with the observed 
increase in fatty acid synthesis, L-dKO mice display increased hepatic 
synthesis of GPLs, in particular via the biosynthetic pathway leading to CL. 
 
Increased cardiolipin accumulation is associated with enhanced 
respiration. 
CLs stabilize the complexes of the electron transport chain (ETC), thereby 
supporting oxidative phosphorylation (OxPhos) (Duncan et al., 2016). 
Expression of ETC complexes was unchanged in L-dKO mice (Figure S5A). 
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However, hepatocytes from L-dKO mice exhibited hyper-tubular mitochondria 
and pronounced cristae, as determined by EM analysis and IF (Figures 5B-C, 
S5B). Hyper-tubular mitochondria and pronounced cristae are associated 
with improved mitochondrial function (Cogliati et al., 2013). To investigate 
mitochondrial function, in particular OxPhos, we measured the oxygen 
consumption rate (OCR) and mitochondrial reserve capacity of primary 
hepatocytes. Primary hepatocytes from L-dKO mice displayed enhanced 
OxPhos and increased mitochondrial reserve capacity, compared to wild-type 
hepatocytes (Figure 5D). Thus, CL accumulation correlates with enhanced 
mitochondrial function. The increase in CL may improve mitochondrial 
function to sustain the enhanced metabolic needs of tumor cells. 
 
mTORC2 promotes fatty acid, sphingolipid and cardiolipin 
accumulation. 
The above suggests that hyperactive mTOR signaling promotes lipid 
synthesis and cancer. To confirm that tumor development is indeed mTOR 
dependent, 8 week-old L-dKO and control mice were chronically treated with 
the ATP competitive mTOR inhibitor INK128, or drug vehicle alone, for 12 
weeks. Chronic INK128 administration reduced mTOR signaling (mTORC1 
and mTORC2) (Figure S6A), and reduced both tumor burden and incidence 
and liver damage (Figures 6A-C, S6B), confirming that tumor development 
was mTOR dependent. Of note, chronic INK128 administration also reduced 
hepatic TG content and hepatocyte size (Figures 6D, S6C). 
Hepatic mTORC1 and mTORC2 are activated in L-dKO mice (Figure 1A). 
To determine whether mTORC1 and/or mTORC2 signaling controls FA and 
lipid synthesis in L-dKO mice, we performed acute pharmacological inhibition 
studies. Eight week-old L-dKO and control mice were treated acutely (24 hr) 
with rapamycin, INK128 or drug vehicle alone. Acute rapamycin treatment 
inhibited mTORC1, whereas acute INK128 administration inhibited both 
mTORC1 and mTORC2 (Figure S6D), as expected (Hsieh et al., 2012). 
Acute INK128 treatment reduced both expression of ACC, FASN, and SCD 
(Figures 6E; 6F quantified in S6E) and, compared to INK128-treated controls, 
hepatic TG content in L-dKO mice (Figure S6F). Acute INK128 treatment 
increased overall hepatic TG in L-dKO and control mice compared to mice 
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treated with drug vehicle alone, likely due to enhanced lipolysis in adipose 
tissue (Kumar et al., 2010) as suggested by increased serum free FA levels 
(Figure S6G). Inhibition of mTORC1 alone (rapamycin) had little-to-no effect 
on expression of hepatic FA synthesis enzymes and hepatic TG content 
(Figures 6E-F and S6E). However, rapamycin insensitive mTORC1 
substrates may still be involved in FA synthesis (Peterson et al., 2011). To 
investigate further a possible role of mTORC1 in the regulation of FA 
synthesis, we examined hepatic expression of FA synthesis enzymes in liver-
specific Tsc1 knockout (L-Tsc1KO) mice. L-Tsc1KO mice exhibited activated 
mTORC1, but not mTORC2, and unaltered expression of FA biosynthetic 
enzymes (Figure 6G). These data suggest that hepatic FA synthesis is likely 
activated by mTORC2. 
To confirm that mTORC2 promotes de novo FA and lipid synthesis, TG 
accumulation and liver cancer development, we deleted Rictor, an essential 
core component of mTORC2, in L-dKO mice. Tsc1loxP/loxP; PtenloxP/loxP mice 
were crossed with RictorloxP/loxP mice expressing Alb-Cre, to generate triple 
knockout (L-TriKO) mice lacking Tsc1, Pten and Rictor (Figure S7A). Rictor 
loss was confirmed at mRNA and protein levels (Figure S7B-C). Immunoblots 
revealed markedly reduced hepatic mTORC2 signaling in L-TriKO mice 
(Tsc1loxP/loxP; PtenloxP/loxP; RictorloxP/loxP; Alb-Cre) compared to control mice 
(Tsc1loxP/loxP; PtenloxP/loxP; RictorloxP/loxP), while mTORC1 signaling was 
unchanged (Figure S7C), confirming the L-TriKO mouse model. Importantly, 
L-TriKO mice displayed reduced expression of ACC, FASN, SCD and their 
transcriptional activator SREBP1c (mature form), and reduced hepatic TG 
content (Figure 7A-B), compared to L-dKO mice. Expression of the SL 
synthesis genes Sptlc1 and Smpd3 was also reduced in L-TriKO mice, 
compared to L-dKO mice (Figure 7A, C). Similarly, immunoblotting of primary 
hepatocytes from knockout and control mice showed reduced CLS1 
expression in L-TriKO mice (Figure S7D). Lipidomic analyses of livers from L-
TriKO, L-dKO and control mice revealed reduced SL and GPL levels, 
including GlcCer and CL(18:≤1), respectively, specifically in L-TriKO mice 
(Figure 7D and Table S5).  Similarly, L-TriKO mice displayed reduced hepatic 
sphinganine and normalized serine levels (Figures 7E, S7E). Collectively, the 
above indicates that mTORC2 activates de novo FA and lipid synthesis. 
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Importantly, in addition to reduced FA and lipid synthesis, L-TriKO mice 
also displayed reduced tumorigenicity (Figures 7F-I, S7F-G). We note that 
the few tumors that arose in L-TriKO mice exhibited increased mTORC2 
activity, as assessed by AKT-pSer473 (Figure S7H), suggesting that such 
tumors were due to ‘escapers’ in which Rictor was not deleted. Thus, it is 
mTORC2 that is lipogenic and oncogenic in L-dKO mice. 
To examine the oncogenic role of mTORC2 in another mouse model of 
NAFLD progressing to HCC, liver specific Rictor knockout mice (LiRiKO) and 
littermate controls were chronically fed a choline deficient, high-fat diet (CD-
HFD) and treated with the hepatic pro-carcinogen diethylnitrosamine (DEN) 
(Wolf et al., 2014). Four out of five LiRiKO mice failed to develop liver tumors 
and exhibited reduced expression of lipogenic enzymes, as compared to 
control mice (n=3) (Figure S8A-B). Of note, tumors that arose in control mice 
displayed elevated AKT-pSer473, FASN and SPT expression, suggesting 
that tumors require lipogenic enzymes for growth (Figure S8B). The above 
underscore the critical role of mTORC2 in lipogenesis and HCC. 
 
Lipogenesis is up-regulated in human hepatosteatosis progressing to 
HCC. 
L-dKO mice display hepatosteatosis progressing to HCC. To examine the 
relevance of this model to human HCC, we investigated mTORC2 activity 
and expression of FA and lipid biosynthetic enzymes in human liver cancer 
cell lines. Human liver cancer cell lines with high AKT-pSer473 also exhibit 
increased expression of FA and lipid synthesis proteins and vice versa 
(Figure S8C). To investigate the functional significance of this correlation, 
HCC cells exhibiting high (Hep 40) and low (PLC) mTORC2 activity were 
treated with a FASN (C75) or SPT (myriocin) inhibitor. At a high dose (200 
nM), C75 killed practically all cells in both cell lines, demonstrating a general 
dependence of tumor cells on de novo FA synthesis (Figure S8D). At lower 
doses (10 nM or 50 nM), Hep 40 cells were more sensitive to FASN inhibition 
(50% reduction) compared to PLC cells. Remarkably, myriocin administration 
killed Hep 40 cells but had no effect on PLC cells, at all doses examined 
(Figure S8D, E). Thus, similar to our findings in L-dKO mice, FA and lipid 
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biosynthesis correlates with mTORC2 activity and is required for proliferation 
in human cancer cells. 
To address the clinical relevance of our findings to HCC development 
in patients, we performed proteomic analysis on HCC and matched non-
tumor biopsies from 18 patients. In 12 patients (one of which presented two 
separate tumors) HCC had progressed from hepatosteatosis, whereas in the 
remaining six patients HCC had progressed from viral (HCV or HBV) 
infection (Table S6). Strikingly, the tumor tissue from the 12 steatotic patients 
displayed high levels of FA and lipid biosynthetic enzymes, and these levels 
exceeded the level in the matched non-tumor samples. In comparison, 
enzyme levels were low in the virus infected (non-steatotic) patients and 
unchanged or reduced in the HCC sample relative to the matched non-tumor 
tissue (Figures 8A, S8F and Table S7). Thus, FA synthesis and lipogenesis 
are upregulated in human HCC that progressed from steatosis, as in L-dKO 
mice. 
To confirm that lipogenesis is upregulated in steatotic tissue, we 
examined liver biopsies from ten hepatosteatotic (NAFLD or NASH), cancer-
free, patients and from two healthy individuals. Immunoblot analyses 
revealed that the rate-limiting enzymes of FA (FASN and ACC) and GlcCer 
(GCS) synthesis were increased in 40% and 80% of the patients, 
respectively, as compared to healthy controls (Figure 8B). Patients exhibiting 
hepatosteatosis that do not show increased de novo lipogenesis may take up 
FA from the diet (Donnelly et al., 2005). Importantly, as observed in L-dKO 
mice, increased FASN, ACC and GCS expression correlated with high 
mTORC2 activity, as assessed by AKT-pSer473 (Figure 8B). Furthermore, 
AKT-pSer473 positively correlated with GlcCer lipid levels in human biopsies, 
as determined by immunoblotting and lipidomic analyses (Figure 8C). Thus, 
mTORC2 may promote sphingolipid synthesis (GlcCer) also in human 
hepatosteatosis that could in turn contribute to HCC development. The above 
results suggest that hepatosteatosis patients would benefit from early 
intervention with lipogenesis inhibitors, or with an mTOR inhibitor(s), to 
prevent progression to HCC. 
 
Discussion 
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Diverse mutations activate mTOR signaling to promote tumorigenesis, but 
tumorigenic mechanisms downstream of mTOR remain poorly defined, in 
particular for mTORC2. We examined tumorigenesis in an mTOR-dependent 
HCC mouse model (L-dKO) and in human patients. We report that mTORC2 
promotes hepatosteatosis and ultimately cancer via fatty acid (FA) and lipid 
synthesis. 
Similar to patients who develop NAFLD that progresses to HCC (Postic 
and Girard, 2008), L-dKO mice exhibit enhanced FA synthesis and thereby 
develop hepatosteatosis, liver damage and HCC. FASN knockdown (or 
orlistat treatment) blocked carcinogenesis. Notably, FASN inhibition did not 
have a detrimental effect in wild-type hepatocytes, exposing a vulnerability 
specific to cancer cells. 
How do FAs promote carcinogenesis? First, FAs are required for lipid 
synthesis, which may in turn be necessary for carcinogenesis. We observed 
that lipid synthesis pathways, in particular de novo SL and GPL synthesis, 
are up-regulated in L-dKO mice, and that Sptlc1 expression is high across 
various human tumors including HCC. Importantly, inhibition of the first 
reactions in de novo SL synthesis or GlcCer synthesis prevented HCC in L-
dKO mice, indicating that up-regulation of lipid synthesis is essential for 
tumorigenesis. Second, enhanced FA synthesis causes hepatosteatosis, a 
pathological accumulation of FAs, which may in turn promote inflammation 
(i.e. NASH) that progresses to HCC (Park et al., 2010). For example, FAs 
could be used to produce the bioactive sphingolipid S1P that signals to 
recruit macrophages (Liang et al., 2013). Consistent with the notion that FAs 
promote tumor development via inflammation, L-dKO mice exhibited up-
regulated Sphk1 and increased S1P levels, which correlated with increased 
STAT3 phosphorylation. The immune system plays an important role in 
hepatosteatosis to HCC progression (Kondylis et al., 2015). We note that L-
dKO mice exhibited both innate and adaptive immune cell infiltration, and that 
in L-dKO mice hepatosteatosis seems to precede inflammation. The role of 
inflammation in mTOR driven tumors, and in particular its promotion by FAs, 
requires further study. 
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How does up-regulation of SL and GPL synthesis (in particularly of 
GlcCer and CL, respectively) promote cancer? First, SL and GPL are 
structural components of membranes and may thereby support tumor growth 
simply as building blocks. Ceramide glycosylation by GCS yields the 
membrane component GlcCer, but also eliminates excess ceramide and its 
anti-proliferative effect (Ogretmen and Hannun, 2004). Importantly, L-dKO 
mice preferentially accumulate GlcCer. Thus, the essential role of GlcCer 
synthesis in tumorgenicity may be two-fold, one is to produce a building block, 
the other is to eliminate ceramide. It is possible that a more complex 
glycosphingolipid (ganglioside), produced from GlcCer is critical for 
tumorigenesis. Second, CL in the inner mitochondrial membrane stabilizes 
complexes of the ETC thereby enhancing energy production and satisfying 
the increased metabolic needs of tumor cells (Peck et al., 2016). Importantly, 
we observed increased CL synthesis, enhanced mitochondrial cristae and 
mitochondrial energy production in liver of L-dKO mice. Third, lipids provide 
second messengers in oncogenic signaling pathways. For example, 
phosphorylated forms of phosphatidylinositol mediate growth factor signaling. 
It remains to be determined whether the increased lipid synthesis observed in 
L-dKO mice affects second messenger levels in oncogenic signaling 
pathways. 
How does mTORC2 regulate FA synthesis? L-dKO mice display 
increased levels of mature SREBP1c and increased expression of SREBP1c 
target genes Acaca, Fasn, Scd and Elovl6. Pharmacological or genetic 
ablation of mTORC2 signaling in L-dKO mice (L-TriKO) prevented SREBP1c 
processing, decreased Acaca, Fasn, and Scd expression, and thereby 
reduced de novo FA synthesis. Thus, mTORC2 promotes de novo FA 
synthesis via SREBP1c, as shown previously (Hagiwara et al., 2012). 
mTORC2 or its effectors may also phosphorylate FA synthesis enzymes 
directly, as recently proposed for ACLY (Chen et al., 2016). Finally, mTORC2 
increases expression of the FA transporter CD36, allowing up-take of FA 
from the bloodstream. 
mTORC1 has also been proposed to stimulate FA synthesis (Ricoult and 
Manning, 2013), for example, in breast cancer cell lines (Ricoult et al., 2015). 
However, mTORC1 alone is insufficient to promote FA synthesis in vivo. First, 
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L-Tsc1KO mice (constitutively active mTORC1) exhibit reduced FA levels and 
are even protected from age and diet induced hepatosteatosis (Cornu et al., 
2014; Kenerson et al., 2015; Kenerson et al., 2011; Yecies et al., 2011). 
Second, activation of mTORC1 is insufficient to activate expression of 
lipogenic genes (Titchenell et al., 2016). Third, liver specific Raptor knockout 
mice (abrogated mTORC1 activity) exhibit unaltered hepatic FA levels, even 
when fed a high fat diet (Umemura et al., 2014). Thus, mTORC2 may play a 
more important role than mTORC1 in hepatic FA synthesis. 
How does mTORC2 activate lipid synthesis? We observed that mTORC2 
controls expression of critical lipid synthesis genes, suggesting a mechanism 
at the level of transcription. However, mTORC2 is functionally at ER-
mitochondria contact sites (Betz et al., 2013), where GPL synthesis and 
exchange occurs. Thus, mTORC2 or its kinase effectors could directly 
phosphosphorylate and activate GPL synthesis enzymes. In skeletal muscle, 
AKT phosphorylates ACLY thereby improving mitochondrial function (Das et 
al., 2015). The mechanism by which mTORC2 activates lipid synthesis 
remains to be determined. Yeast TORC2 stimulates sphingolipid synthesis 
via post-translational regulation of SPT and ceramide synthase (Berchtold et 
al., 2012; Muir et al., 2014; Roelants et al., 2011). 
Does mTORC1 play a role in lipid synthesis in L-dKO mice? mTORC1 
stimulates pyrimidine biosynthesis via phosphorylation of CAD and 
transcriptional activation of the pentose phosphate pathway (Ben-Sahra et al., 
2013; Robitaille et al., 2013). The pyrimidines uridine diphosphate (UDP) and 
cytidine diphosphate (CDP) are required for the rate-limiting reactions in 
GlcCer and GPL synthesis, respectively. Indeed, L-dKO mice display 
increased CAD phosphorylation. Thus, our data favor a model in which 
mTORC1 and mTORC2 converge on lipid synthesis to drive tumorigenesis. 
Collectively, we demonstrate that mTORC2 promotes tumorigenesis via 
FA and lipid synthesis. Several FA and lipid blocking therapies are being 
evaluated in ongoing clinical trials (Beloribi-Djefaflia et al., 2016). Our data 
suggests that cancer patients exhibiting high mTORC2 signaling, particularly 
steatotic patients potentially progressing to HCC, should be considered for 
such therapies.  
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Figure legends 
 
Figure 1. L-dKO mice develop HCC and exhibit enhanced de novo FA 
and lipid synthesis. 
(A) Immunoblots of liver extracts from ad-libitum fed 4, 8, 12, and 20 week-
old L-dKO and control mice (n=6 per group). SREBP1c (p) precursor (m) 
mature. 
(B) Representative H&E (Hematoxylin and Eosin), SR (Sirius Red), PAS 
(Periodic Acid Schiff) staining of HCCs (20 week) L-dKO and control mice. 
Asterisks and arrows indicate HCC and HCC border (fibrosis), respectively; 
white scale bar, 100 µm. 
(C) Lipid biosynthetic enzymes detected by immunoblotting or proteome 
analyses of livers from young mice (4, 8 and 12 week; n=6 per group), or 
detected in immunoblotting, proteome or transcriptomic analyses from HCCs 
(n=12). Color coded bars indicate relative expression from young mice on the 
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left and HCC on the right (STAR Methods). n.c., not changed; n.d., not 
detected; down, down-regulated; up, up-regulated. ACLY-pSer455 and 
enzymes experimentally inhibited, FASN (shFASN/orlistat), SPT (myriocin) 
and GCS (shGCS) are indicated. pE/H, phoshoethanolamine/hexadecanal. 
(D) Representative images and quantification of HCCs stained with Oil-Red-
O (ORO) (n=3); au, arbitrary unit; white scale bar, 100 µm. 
(E) Hepatic triglyceride (TG) from ad-libitum fed L-dKO and control mice 
(≥n=4). Data are represented as mean ± SEM; p value by two-tailed unpaired 
t-test. See also Figure S1 and Tables S1-S2. 
 
Figure 2. Inhibition of FASN or GCS prevents hepatocellular carcinoma. 
(A) Tumor number and size and (B) serum ALT, AST and LDH levels of L-
dKO mice chronically treated with orlistat or the drug vehicle. 
(C-F) L-dKO mice infected with AAV-shFASN (n=4), AAV-shGCS (n=6) or 
control AAV-shSCRMBL (n=5). Tumor number and size (C), representative 
whole-liver images and histological analyses (D); scale bar, 1 cm; arrows 
indicate tumors; scale bar, 100 µm. Number of Ki67 positive hepatocytes per 
10X magnification (n=3) and (E) serum ALT, AST and LDH levels from L-
dKO mice infected with AAV-shScrmbl (n=5), AAV-shFASN (n=4) or AAV-
shGCS (n=6) (F). Data are represented as mean ± SEM; p value by two-
tailed unpaired t-test. See also Figure S2. 
 
Figure 3. L-dKO mice accumulate SLs and GPLs in the liver. 
(A) Relative hepatic mRNA (quantitative PCR) from 4, 8 and 20 week L-dKO 
and control mice (n=6 per group); au, arbitrary unit. 
(B) Hepatic lipid z-score enrichment expressed as L-dKO/control mice of 
indicated ages (n=6 per group; STAR Methods); up-regulated (up-reg.) and 
down-regulated (down-reg.). GlcCer, glucosylceramide; SM, sphingomyelin; 
CL, cardiolipin; Cer, ceramide; PS, phosphatidylserine; PI, 
phosphatidylinositol; CerP, ceramide phosphate; LysoPC, lyso-
phosphatidylcholine; OH, hydroxyl; DH, dihydro. 
(C) Hepatic sphinganine in 4, 8, 12 and 20 week-old mice (n=6). Data are 
represented as mean ± SEM; p value by two-tailed unpaired t-test. See also 
Figure S3 and Table S3. 
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Figure 4. mTOR promotes de novo SL synthesis, thereby tumor 
development. 
(A) Tumor number and size in 20 week-old L-dKO mice after chronic 
myriocin or drug vehicle administration. 
(B) Volcano plot of the major lipid species regulated in livers from myriocin-
treated mice compared to drug vehicle-treated mice (L-dKO/control). GlcCer 
in blue. Black line indicates significant from non-significant alterations for a 
threshold of 0.75 Log2-Fold. 
(C) Principal component analysis (PCA) of lipidomic analysis from myriocin-
treated mice. Discrimination between L-dKO and control mice driven by 
principal component 1 (dashed circles). Principle component 2 drove the 
separation between myriocin-and vehicle-treated groups (closed circle). 
(D) Sptlc1 expression (TPM, STAR Methods) across various non-tumorous 
and tumorous tissues. Each dot represents information from one patient. 
Data are represented as mean ± SEM; p values by two-tailed unpaired t-test. 
See also Figure S4 and Table S4. 
 
Figure 5. mTOR promotes CL synthesis and OxPhos in hepatocytes. 
(A) Immunoblots of liver extracts from 4, 8, 12, and 20 week-old L-dKO and 
control mice. Arrow specifies PTPMT1. 
(B) Representative confocal images of primary hepatocytes, perfused from 8 
week-old L-dKO and control mice, stained by MitoTracker-Red. Arrows 
indicate tubular mitochondrial networks. Nuclei, blue (DAPI); scale bar, 10 
µm. 
(C) Representative electron micrographs of hepatocytes from L-dKO and 
control mice (n=3). Arrows indicate mitochondria cristae. Scale bar, 500 nm. 
(D) Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate 
(ECAR) analyses of primary hepatocytes perfused from 8 week-old L-dKO 
and control mice (n=3). The time at which a given compound was added is 
indicated; background contained no cells. Data are represented as mean ± 
SEM. See also Figure S5. 
 
Figure 6. mTOR inhibition prevents FA accumulation and HCC. 
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(A-C) L-dKO mice chronically treated with INK128 (INK) or a vehicle (n=7 per 
group). Representative whole-liver images (scale bar, 1 cm, arrows indicate 
tumors), liver tumor number and size (A) and incidence, (B) serum ALT, AST 
and LDH levels (U/L) and (C) hepatic triglyceride (TG) (D). 
(E-F) Liver extracts from 8 week-old L-dKO and control mice (n=4) acutely 
treated with rapamycin (rapa) or INK128 (INK) or a vehicle (vehr and vehi, 
respectively) mRNA (E)  immunoblots (F); au, arbitrary unit.  
(G) Immunoblots of liver lysates from L-Tsc1, L-dKO and control mice (n=4 
per group); n.s., not significant. Data are represented as mean ± SEM; p 
values by two-tailed unpaired t-test. See also Figure S6. 
 
Figure 7. mTORC2 promotes FA, lipid synthesis and tumorigenesis. 
(A) Immunoblots of liver extracts from 20 week-old L-dKO, L-TriKO and 
littermate control mice (n=4 per group). Arrow specifies mature SREBP1c (m) 
from precursor (p). 
(B-C) 20 week-old L-dKO (n=6), L-TriKO (n=4) and pooled controls (n=8). 
Hepatic triglyceride (TG) (B) Relative mRNA (C); au, arbitrary unit. 
(D) Hepatic lipid enrichment in L-dKO/control and L-TriKO/L-dKO mice (n=4 
per group). 
(E) Hepatic sphinganine in 20 week-old L-dKO and L-TriKO mice, normalized 
to control mice (n=4 per group) (STAR Methods). 
(F-H) 20 week-old L-dKO and L-TriKO mice. Liver tumor number, size (F) 
and incidence (G). 
(H) Representative histological analyses from livers of L-TriKO and control 
mice; scale bar, 100 µm. 
(I) Survival proportions of L-dKO and L-TriKO mice (Kaplan-Meier, **** 
p<0.0001 for both Mantel-Cox and Gehan-Breslow-Wilcoxon tests). Data are 
represented as mean ± SEM; p values by two-tailed unpaired t-test. See also 
Figure S7 and Table S5. 
 
Figure 8. Lipogenesis is up-regulated in human hepatosteatosis 
progressing to HCC, and correlates with mTORC2 activity. 
(A) Protein expression in HCC compared to a non-HCC region from the 
same patient. Each box represents data from one HCC. n.c., not changed; 
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n.a., not applicable; down, down-regulated; up, up-regulated in proteome 
(STAR methods). 
(B) Immunoblots from liver biopsies from healthy individuals (ctrl, n=2), 
NAFLD (n=5) and NASH (n=5) patients. 
(C) Nonlinear regression (R square) of hepatic glucosylceramide (GlcCer) 
level and AKT-pSer473 in human liver biopsies. Data are represented as 
mean ± SEM; p value by one-tailed unpaired t-test. See also Figure S8 and 
Tables S6-S7. 
 
STAR METHODS 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and request for resources and reagents should be 
directed to and will be fulfilled by the Lead Contact, Michael N. Hall 
(m.hall@unibas.ch). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Patient Needle-Core Biopsies.  Patients were recruited in the Clinic for 
Gastroenterology and Hepatology of the University Hospital Basel, 
Switzerland.  They gave written informed consent to donate liver biopsy 
specimens for research.  Study protocol was approved by the Ethics 
Committee of the Canton Basel, Switzerland.  The biopsies were performed 
under ultrasound guidance using a coaxial needle technique allowing 
repetitive sampling from the same part of a focal lesion with a full-core biopsy 
instrument (BioPince; Angitech).  Diagnosis of HCC was made by 
histopathological analysis.  The gender and the age of hepatosteatosis and 
HCC patients can be found in Table S6. 
 
Animals.  Liver-specific tuberous sclerosis complex 1 (Tsc1) and 
phosphatase and tensin homolog (Pten) double knockout mice were obtained 
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by crossing Tsc1loxP/loxP mice with PtenloxP/loxP mice (Horie et al., 2004) to 
transgenic mice expressing Cre recombinase under the control of the 
hepatocyte-specific albumin promoter (Alb-Cre), to generate liver specific 
double knockout (L-dKO) mice.  Liver-specific TSC1 knockout mice (L-Tsc1) 
were generated as described (Cornu et al., 2014).  Tsc1loxP/loxP; PtenloxP/loxP 
mice were crossed to Rictor loxP/loxP; Alb-Cre (Hagiwara et al., 2012) to obtain 
(Tsc1loxP/loxP; PtenloxP/loxP; Rictor loxP/loxP; Alb-Cre) liver specific triple knockout 
(L-TriKO mice) mice.  L-TriKO mice were born according to Mendelian ratios 
and gained weight normally (not shown).  As controls, male littermate 
Tsc1loxP/loxP mice or Tsc1loxP/loxP; PtenloxP/loxP mice or Tsc1loxP/loxP; PtenloxP/loxP; 
Rictor loxP/loxP mice (which do not express Cre-recombinase) were used.  Mice 
were maintained on mixed genetic background (C57BL/6J, 129/SvJae, 
BALB/cJ).  Both L-dKO mice (Tsc1loxP/loxP; PtenloxP/loxP; Alb-Cre) and L-TriKO 
(Tsc1loxP/loxP; PtenloxP/loxP; Rictor loxP/loxP; Alb-Cre) mice were born viable at the 
expected Mendelian ratio and displayed normal fertility.  PCR genotyping 
was performed as described (Cornu et al., 2014).  Mice were maintained 
under temperature and humidity-controlled conditions, lights on at 6:00am 
and off at 6:00pm.  In all experiments, mice were sacrificed between 6:00 to 
7:00am and were ad-libitum fed, unless mentioned otherwise.  All 
experiments were conducted with male mice, and performed in accordance 
with federal guidelines and were approved by the Kantonales Veterinaeramt 
of Kanton Basel-Stadt. 
 
Choline deficient (CD) high-fat diet (HFD) and diethylnitrosamine (DEN) 
treatment.  4 week-old liver specific Rictor knockout (LiRiKO, Rictor loxP/loxP; 
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Alb-Cre) and control (Rictor loxP/loxP) mice were intraperitoneally injected with 
DEN (25 mg/kg bw) once a day for one week, and were ad-libitum fed with 
CD-HFD for about 10 months.  Afterwards, mice were sacrificed and liver 
tumors were counted, as described below.  
 
Human liver cancer cell lines.  All human liver cells were grown in DMEM 
high glucose media supplemented with 10 % FBS, glutamine (GlutaMAX, 
Gibco), non-essential amino acids (Gibco) and penicillin-streptomycin (Gibco). 
For colony growth assays, Hep 40 and PLC cells were seeded in 12 well 
plate (Corning) and grown to reach 80 % confluency.  C75 or myriocin were 
solubilized in DMSO and added to fresh pre-warmed media in 50ml tubes 
(Falcon).  Aliquots from the above media containing inhibitors (C75 or 
myriocin or the drugs vehicle alone) were then added to the proper wells.  24 
hr post treatment cells were fixed for 5 min with 10 % formalin and stained for 
30 min with 0.05 % Crystal violet dye, washed and analyzed.  Quantification 
was performed using Fiji.  The sex and the age of the patients who were the 
source of the cells are indicated in Table S6.   
 
METHODS DETAILS 
 
Virus administration.   
AAV-albumin-shRNA-FASN-RFP was used for the knockdown of the gene 
FASN. AAV-albumin-shRNA-GCS-RFP was used for the knockdown of the 
gene Ugcg. AAV-albumin-shRNA-Scrmbl-RFP was used as a control. All 
viruses were purchased from Vector BioLabs. Mice were infected with AAVs 
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by tail-vein injection (5*10^11 viral genome, unless otherwise mentioned).  
Knockdown sequences were confirmed both in vitro (not shown) and in vivo.  
To examine the effect on tumor growth mice were sacrificed about three 
months post infection. 
 
Whole-body metabolic analysis.  RER (Respiratory Exchange Rate), 
locomotor activity and food consumption were measured in 30 min intervals, 
for the indicated time using a comprehensive laboratory animal monitoring 
system (CLAMS, Linton Instrumentation and Columbus Instruments).  
Measurement was performed over 72 hr, after providing 24 hr of 
acclimatization.  Mice had free access to food and water.  Body fat 
composition was assessed in ad-libitum fed mice, by nuclear magnetic 
resonance imaging (Echo MRI mouse, Echo Medical Systems, Houston, 
USA). 
 
Pharmacological treatments.  For chronic mTOR inhibition, INK128 or the 
drug vehicle alone was orally given to 8-week-old L-dKO mice (n=7) and 
littermate control (n=7) mice, at dose of 1 mg/kg bw, every other day for 12 
weeks.  INK128 was dissolved in 5 % 1-methyl-2-pyrrolidinone, 15 % 
polyvinylpyrrolidone K30, and 80 % water, as described (Hsieh et al., 2012).  
Rapamycin was dissolved as published (Cornu et al., 2014) in 5 % (vol/vol) 
PEG-400, 4 % (vol/vol) ethanol, and 5 % (vol/vol) Tween 80, and was 
injected intraperitoneally.  For acute mTOR inhibition studies, rapamycin or 
INK128 or the drugs vehicles were administered to 8-10 weeks-old L-dKO 
and littermate controls (n=4 per group), twice (6 am and 6 pm) over 24 hr, at 
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doses indicated above.  Orlistat (Xenical) was orally given to 6 to 8 week-old 
L-dKO (n=4) and control mice (n=5) at a dose of 120 mg/kg bw, for 12 weeks, 
daily, as described (Sounni et al., 2014).  Myriocin was intraperitoneally 
administrated to 8 week-old L-dKO (n=5 myriocin, n=6 vehicle) and control 
(n=5 myriocin, n=4 vehicle), at a dose of 0.3 mg/kg bw, every other day, for 
12 weeks.  For assessment of liver tumor burden, in all cases unless 
otherwise indicated, mice were sacrificed at the 20th week of age.  Mice were 
euthanized and their livers quickly removed.  Subsequently, externally visible 
tumors (>0.2 mm) were counted and measured.  Were indicated tumors were 
resected and subsequently used for biochemistry, histology, and/or OMICS 
analyses: (phospho)proteomics, lipidomics, metabolomics. 
 
BrdU (5-Bromo-2’-deoxy-Uridine) examination.  To evaluate cell 
proliferation in vivo in tumors, L-dKO and control mice at 16 weeks of age (at 
which time tumor and non-tumor regions can be readily discriminated) were 
intraperitoneally injected with 100 mg/kg bw BrdU once a day, at 6:00pm for 
three days.  At 6:00am of the fourth day, mice were sacrificed and livers were 
removed.  Liver lobes, containing both tumor and non-tumor regions, were 
fixed in 4 % paraffin and were then used for immunofluorescence imaging 
using the BrdU in situ detection kit.  HCCs were confirmed by histological 
analyses (H&E) of serial sections. 
 
Serum parameters.  Prior to liver dissection, blood was collected from the 
inferior vena cava using a 25-gauge needle.  Blood was placed immediately 
into a heparin-coated tube (BD microtainer) to obtain serum.  Subsequently, 
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50 μl of serum was diluted three times and loaded to a Cobas c 111 analyzer 
(Roche).  Serum parameters: circulating transaminases (ALT, AST), LDH 
and albumin were measured.  Plasma free-fatty acid levels were determined 
using a commercial kit (HR Series NEFA-HR (2) and Cayman). 
 
Isolation of primary cells and cell culture.  For isolation of primary mouse 
hepatocytes, 8-10 week-old L-dKO and controls were used.  Primary 
hepatocytes were obtained by liver perfusion.  Shortly, peritoneal cavity was 
opened and the inferior vena cava was cannulated using a 23-gauge needle 
catheter.  Cannula was clamped using a surgical clip.  Liver was then 
perfused with pre-warmed (37 °C) Ca2+ and Mg2+ free-HBSS++ containing 1 
mM EGTA, at a rate ranging from 5 to 10 mL/min, prior to chest dissection.  
The aorta was ligated and the portal vein was transected.  Liver was then 
perfused with pre-warmed (37 °C) HBSS++ with Ca2+ and Mg2+ containing 
collagenase digestion solution (collagenase type II and DNase I (10 μg/mL)), 
at a rate of 7.5 mL/min.  The perfused and digested liver was then carefully 
dissected and placed in a petri dish containing ice-cold HBSS++.  Glisson 
capsule was then gently teased with forceps to get the cell suspensions.  Cell 
suspensions were filtered through gauze to remove undigested or connective 
tissue and centrifuged 650 × g for 5 min.  Thereafter, re-suspended with 
HBSS++ and followed by 3 min at 35 × g centrifugation to obtain parenchymal 
cells (pellet) and non-parenchymal cells (supernatant).  Parenchymal cell 
suspensions, containing vital hepatocytes, were used for culture.  Briefly, 
hepatocytes were resuspended in pre-warmed culture media (DMEM high 
glucose with 10 % fetal bovine serum (FBS)).  Primary hepatocyte 
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maintenance supplements, including dexamethasone ITS (insulin, transferrin, 
selenium complex) and glutamine were added to the media. 
 
OCR and ECAR measurements.  Measurements were performed with an 
XF96 Extracellular Flux Analyzer (Seahorse Bioscience of Agilent) following 
manufacturer instructions.  2×104 hepatocytes were seeded into 96 culture 
plate (Seahorse Bioscience of Agilent) overnight or measured 1 hr post-
seeding.  Media was exchanged prior to the measurement.  Oligomycin 
inhibits ATP synthase (complex V), FCCP uncouples oxygen consumption 
from ATP production, and rotenone and antimycin A inhibit complexes I and 
III, respectively.  All drugs were obtained from Seahorse Bioscience of 
Agilent. 
 
FACS analysis.  To obtain immune cells (non-parenchymal), livers from 4, 8 
and 20 week-old littermate L-dKO and control mice were perfused as 
described above.  The non-parenchymal cell suspension was resuspended in 
HBSS++ supplemented with 0.5 % BSA.  Then, non-parenchymal cell 
suspension was filtered through a 100 µm cell strainer (Corning) and 
centrifuged for 500 g for 10 min and incubated in an Fc-block (BD 
Biosciences), and stained with CD45R (B220) PerCP-Cyanine5.5 (Thermo 
Fisher) and Live/Dead Fixable Dead Cell Kit (Thermo Fisher).  Stained 
immune cell were analyzed using FACS Canto II (BD Biosciences).  
 
RNA isolation and quantitative reverse transcriptase PCR.  Total RNA 
was isolated from 50 mg of mouse livers.  Liver samples were homogenized 
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for 30 s bead beating in lysing matrix D tubes (Q-Biogene) containing 1 mL of 
TRIzol reagent (Sigma).  After chloroform extraction and centrifugation, 
samples were mixed with 600 μL of 70 % ethanol, and the extraction was 
continued with the RNeasy kit (Qiagen).  DNase digestion was performed 
using RNase-Free DNase Set (Qiagen).  cDNA synthesis was performed 
using SuperScript III reverse transcriptase (Invitrogen).  Quantitative real-
time PCR was done using the fast SYBR green mix (Applied Biosystems) 
and quantitated using Applied Biosystems StepOnePlus Real-Time PCR 
Systems (Applied Biosystems).  Relative expression levels were determined 
by normalizing each CT values (duplicate or triplicate runs of each sample) to 
cyclophilin expression using the ∆∆CT method.  The sequence for the 
primers used in this study are indicated in Table S8. 
 
Protein isolation and Immunoblotting.  For mouse samples, at 6:00am 
mice were euthanized, livers were rapidly dissected, flash-frozen into liquid 
nitrogen, and stored at -80 °C.  For protein extraction, liver tissues were 
homogenized using a polytron, in ice-cold lysis buffer (100 mM Tris (pH 7.5), 
2 mM EDTA, 2 mM EGTA, 0.5 M mannitol) supplemented with 1 % Triton X-
100, protease and phosphatase inhibitor mixture tablets (Roche).  Lysates 
were centrifuged at 10,000 × g for 10 min at 4 °C, afterwards pelleted cell 
debris was removed.  Total protein concentration was assessed (BCA 
Protein Assay; Thermo Scientific).  Subsequently, 20 μg of proteins were 
loaded on SDS/PAGE and transferred to a nitrocellulose membrane.  For 
human samples, liver biopsies were snap frozen into liquid nitrogen and 
stored at -80 °C.  Subsequently, liver biopsies were pulverized using a 
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precooled in-house-constructed metal mortar (‘cryogenic grinding’, as 
described below).  Protein extraction for proteome and phosphoproteome 
analyses was performed using a urea based lysis buffer.  Afterwards, lysates 
were vortexed, sonicated, centrifuged and protein concentration was 
assessed using Bradford Protein Assay (see section ‘proteome and 
phosphoproteome’).  The antibodies used for immunoblotting, 
immunofluorescence or immunohistochemistry can be found in the Key 
Resources Table.  For detection, Supersignal west pico chemiluminescent 
substrate or Supersignal west femto maximum sensitivity substrate (Pierce) 
was used. 
 
Histology.  Mice were euthanized, livers quickly dissected and fixed in 4% 
paraformaldehyde.  After overnight dehydration through several steps of 
ethanol, tissues were then embedded into paraffin wax blocks.  Afterwards, 
embedded-tissues were cut into 4 μm-thick sections placed on SuperFrost 
slides (Thermo Scientific).  Slides were then stained with: Hematoxylin and 
Eosin (H&E) or Periodic Acid Schiff (PAS) Stain Kit (Mucin Stain) or Picro 
Sirius Red Stain Kit (Connective Tissue Stain), according to manufacturers’ 
protocols. 
 
Immunofluorescence (IF) and immunohistochemistry (IHC). 
For IF or IHC, mouse liver samples were fixed with 4 % neutral buffered 
paraformaldehyde and paraffin embedded according to standard protocol.  
After de-paraffinization and antigen retrieval steps 4 μm-thick serial sections 
used for immunostaining.  Primary antibodies used were against: RFP, FASN, 
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Ki67 or AKT-pSer473.  Alexa Fluor secondary antibodies from Invitrogen Life 
Technologies were used.  DAPI was used for nuclear counterstaining. 
 
Immunocytochemistry.  For immunocytochemistry, freshly isolated primary 
hepatocytes, obtained by liver perfusion of L-dKO or control mice as 
described above, were placed on glass coverslips (thickness number 1,5 
from VWR) in media containing 12-well culture plate.  After cells were 
attached and equally confluent, coverslips were used for immunocytostaining.  
Briefly, coverslips were placed in a homemade box-holder to keep humidity.  
After a quick washing step using pre-warmed PBS, cells were incubated for 
45 min with MitoTracker red CMXRos diluted in pre-warmed media and 
placed in 37 °C.  Subsequently, cells were washed, fixed, permeabilized and 
were immediately used for staining with anti-GCS or -SPT specific antibodies.  
Alexa Fluor secondary antibodies from Invitrogen Life Technologies were 
used.  DAPI nuclear counterstaining was used.  Coverslips were mounted on 
a glass slide and sealed using nail polish.  Slides were then visualized using 
a scanning confocal “LSM800 Inverted“ with AirScan. 
 
Frozen sections.  Mouse livers were dissected into the different lobes and 
immediately immersed in Optimum Cutting Temperature (O.C.T.) compound 
and frozen in 2-methylbutane precooled in liquid nitrogen.  Afterwards, 
tissues were cut into 10-μm-thick sections using a cryostat microtome, placed 
on glass slides on SuperFrost slides (Thermo Scientific), air dried, and stored 
at -80 °C.  Subsequently, slides were warmed at RT and stained with ORO 
(Sigma) according to standard protocol.  Frozen sections stained by ORO 
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dye were imaged using a Leica upright widefield microscope (DM6000B) and 
neutral lipid droplet size and number were quantified using Fiji.  Detection of 
GlcCer was done in a lipid preservative method.  Frozen liver sections from 8 
and 20 week-old L-dKO, L-TriKO and control mice were warmed at RT and 
washed twice with PBS, subsequently incubated for 1 hr with 5 % goat serum 
for blocking.  Anti-glucosylceramide antibody (GlycoBiotechTM) was diluted 
with PBS/1% BSA and left for overnight at 4 °C.  The same buffer was used 
to dilute an Alexa Fluor® 488 conjugate secondary antibody, followed by 2 hr 
incubation at RT.  Stained sections were mounted with Vectashield H-1000 
(Vector Laboratories, Burlingame, CA).  Images were taken using a wide-filed 
DeltaVision microscope (Olympus IX71) and were deconvoluted.   
 
Image processing.  IHC, H&E, SR, PAS and ORO images were all taken 
using a Leica upright widefield microscope (DM6000B) and scanned using a 
Zeiss Axio Scan.Z1 Slide Scanner.  Hepatocyte size was calculated from 
liver samples that were stained with H&E using ImageJ (Fiji).  Number and 
size of hepatic lipid droplets were quantified from liver frozen-sections 
stained for ORO using ImageJ.  Number of Ki67 positive hepatocytes, per 
10X magnification field, was performed using a wide-filed DeltaVision 
microscope (Olympus IX71). 
 
Hepatic triglycerides (TG) measurement.  Hepatic TG extraction was 
performed as described (Hagiwara et al., 2012).  Briefly, ~ 50 mg of mouse 
liver tissue was homogenized in a cold room, for 30 s (x4, with a 3 min break 
on ice in between, to prevent heating) bead beating in lysing matrix D tubes 
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(Q-Biogene) containing 1 mL chloroform:methanol (2:1).  Tissue lysate was 
transferred into a glass tube and 1 mL of distilled water was added.  
Subsequently, tubes were vigorously vortexed for 2 min and centrifuged at 
800 × g for 10 min at 4 °C.  Then, the upper aqueous phase was discarded 
and the lower solvent phase was dried under nitrogen gas at 50 °C, followed 
by resuspension with 1 mL of chloroform.  TG were then separated by Solid 
Phase Extraction (SPE) column (Interchim) and dissolved in 
chloroform/Triton X-100 (1 %).  Triglyceride levels determined using a 
commercial kit according to manufacturer instructions (TG PAP 150; 
Biomérieux). 
 
Proteome and phosphoproteome.  For time-course proteome analysis 4, 8 
and 12 week-old L-dKO and control mice were overnight fasted.  At 6:00am 
mice were euthanized and livers dissected (n=6 per group).  For analysis of 
liver tumors, livers from 20 week-old L-dKO mice (n=4) were dissected and 
separated into individual lobes and tumors (3 tumors per mouse) were micro-
dissected, whole-liver samples from 20 week-old control mice (n=6) were 
used as control.  Tissues were immediately snap-frozen in liquid nitrogen.  
For protein extraction, we performed a ‘cryogenic grinding’, in which a frozen 
liver biopsy was crushed into a fine powder, using an in-house-constructed 
metal mortar, pre-cooled on dry ice.  Subsequently, crushed liver tissues 
were homogenized using a polytron.  The lysates were transferred into a 
cooled 1.5-mL tube containing 150-400 μL lysis buffer (50 mM Tris-HCl (pH 
8.0), 8 M urea, 150 mM NaCl, 1 mM PMSF, protease and phosphatase 
inhibitor mixture tablets (Roche), 100 mM sodium pyrophosphate/β-
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glycerophosphate/NaF/NaN3/ para-nitrophenylphosphate).  The lysates were 
vortexed vigorously for 5 min, then sonicated in a VWR Ultrasonic cleaner 
bath (USC300T) for 1 min.  Sonication was repeated three times with 2 min 
cooling phases in between.  Samples were then centrifuged at 2500 × g for 
10 min at 15 °C to remove cell debris.  Protein concentration in the 
supernatants was determined by the Bradford Protein Assay.  Proteins were 
reduced with 2.5 mM DTT for 1 hr at 37 °C, and alkylated with 50 mM 
iodoacetamide for 30 min at room temperature in the dark.   
The urea concentration was reduced to 4 M with 25 mM Tris-HCl, pH 8.0.  
Proteins were digested with two rounds of endoproteinase LysC (1:100w/w, 
Wako) at 37°C for 2 hr.  The urea concentration of the LysC digest was 
reduced to approximately 1.2 M with 100 mM Tris-HCl, pH 8.0.  
Subsequently, trypsin digestion (1:100 w/w) was for 2 hr at 37 °C, followed by 
a second round of trypsin digestion (1:100 w/w) overnight at 37 °C.  Digestion 
was stopped by adding TFA to 0.4 % (vol/vol) final concentration.  The digest 
was centrifuged at 12,000 rpm for 10 min at RT and the pellet was discarded.  
For strong cation exchange chromatography (SCX), the peptides were 
desalted on a C18 reverse-phase SepPak cartridge (Waters).  The peptide 
load was kept to about 5 % (w/w) of the weight of the column packing.  The 
cartridge was primed with 5 mL 100 % acetonitrile, washed with 5 mL 50 % 
AcCN containing 0.5 % AcOH and equilibrated with 10 mL 0.1 % TFA.  The 
peptides were applied to the SepPak cartridge and washed with 20 mL of 
0.1 % TFA.  Finally, the cartridge was washed with 1 mL of 0.5 % AcOH and 
the peptides were eluted with 4 mL of 80 % AcCN / 0.5 % AcOH. The peptide 
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concentration was estimated, afterwards peptide elute was dried in a 
SpeedVac. 
 
SCX (Strong Cation Exchange) chromatography.  SCX peptide 
fractionation was done on a HiTrap SP cartridge (GE Healthcare).  A HiTrap 
SP cartridge was washed twice with 1 mL of SCX buffer A (5 mM KH2PO4 
(pH 2.65), 30 % AcCN).  Then, the cartridge was equilibrated twice with 1 mL 
of SCX buffer B (5 mM KH2PO4 (pH 2.65), 30 % AcCN containing 500 mM 
KCl), followed by re-eqilibration with 2 mL of SCX buffer A.  The dried 
peptides were dissolved in 2 mL of SCX starting buffer (5 mM KH2PO4 (pH 
2.65), 30 % AcCN) and applied onto the HiTrap SP cartridge.  The flow-
through was collected.  Bound peptides were desorbed in a stepwise manner 
with 1 mL each of SCX buffer A containing 50 mM, 100 mM, 150 mM, 250 
mM, 350 mM, and 500 mM KCl.  Fractions were collected individually and the 
peptide concentration was estimated at 280 nm.  The fractions were dried in 
a SpeedVac and peptides were then desalted on SepPak cartridges (the size 
of the cartridge was adjusted to the peptide load).  The peptide concentration 
was measured at 280 nm.  20 % of each fraction was used for subsequent 
proteome analysis by LC-MS/MS (see below). 
 
Phosphopeptide enrichment.  Desalted peptides from the individual SCX 
fractions were dissolved in TiO2-binding buffer to obtain a peptide 
concentration of 1 μg/ μL (Kettenbach and Gerber, 2011).  TiO2 beads (GL 
Sciences Inc.) equilibrated in binding buffer were then added to the peptide 
solution.  Adsorption of the peptides to the TiO2 beads was done at RT for 1 
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hr with vigorous shaking.  The beads were pelleted at 3000 rpm for 2 min and 
washed three times with 50 %AcCN/0.1 % TFA.  Bound peptides were eluted 
with 50 mM K2HPO4, pH 10.  The eluted peptides were immediately acidified 
with 5 % formic acid.  The enriched phosphopeptide pool was desalted on 
Stage Tips (Thermo Scientific) according to manufacturer’s 
recommendations, and dried in a SpeedVac. 
 
LC-MS/MS analysis for (phospho)proteome.  The dried phosphopeptides 
were dissolved in 20 μL of 0.1 % AcOH, 0.005 % TFA.  Peptides from the 
proteomes and phosphoproteomes were analyzed by capillary LC-MS/MS 
using a homemade separating column (0.075 mm × 18 cm) packed with 
Reprosil C18 reverse-phase material (2.4 μm particle size, Dr. Maisch, 
Ammerbuch-Entringen, Germany).  The column was connected on line to an 
Orbitrap FT hybrid instrument (Thermo Scientific, Reinach, Switzerland).  The 
solvents used for peptide separation were 0.1 % acetic acid in water/0.005 % 
TFA (solvent A) and 0.1 % acetic acid/0.005 % TFA and 80 % acetonitrile in 
water (solvent B).  2 μl of peptide digest was injected with a Proxeon Easy-
LC capillary pump (Thermo Scientific) set to 0.3 μl/min.  A linear gradient 
from 0 to 40 % solvent B in solvent A in 190 min was delivered with the nano 
pump at a flow rate of 300 nL/min for the proteome, while a shorter linear 
gradient of 95 min under identical conditions for the phosphoproteome was 
used.  At the end of the linear gradient, the percentage of solvent B was 
increased to 75 % in ten min.  The eluting peptides were ionized at 2.5 kV.  
The mass spectrometer was operated in data-dependent mode.  The 
precursor scan was done in the Orbitrap set to a 60,000 resolution, while the 
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fragment ions were mass analyzed in the LTQ instrument.  A ‘top ten method’ 
for the phosphoproteome, and a ‘top twenty method’ for the proteome were 
run so that the ten or twenty most intense precursors were selected for 
fragmentation. 
 
Protein identification and data processing.  The LC-MS/MS data were 
searched with Proteome Discoverer 1.4 (Thermo Scientific) set to Mascot 
and Sequest HT search engines with 10 ppm precursor ion tolerance, while 
the fragment ions were set to 0.6 Da tolerance.  Modifications were set to: 
carbamidomethyl-cysteine, protein N-terminal acetylation, oxidized 
methionine, and phosphorylation for serine, threonine, and tyrosine.  The 
peptide search matches were set to ‘medium confidence’, which corresponds 
to 5 % false discovery rate.  For the searches, the Swiss-Prot KB database 
set to M. musculus was used for Mascot, while for Sequest HT, a local 
databank was constructed by extracting all M. musculus entries from 
UniProtKB.  Two missed cleavages were allowed during the searches.  The 
peptide false-discovery rate was set to 2 %. 
 
Label-free proteome quantification. The LC-MS/MS RAW files were 
analyzed with the Progenesis software (Non-linear Dynamics, Waters).  
Alignment was accepted when at least 80% of all features could be matched.  
The search results from Proteome Discoverer were then imported into the 
aligned Progenesis files.  Only phosphopeptides were further evaluated 
whose site localization probability was ≥75%.  The intensities of all identified 
features were exported via Excel into a FileMaker database. 
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Proteome of human HCC biopsies.  Human HCC biopsies were measured 
by sequential window acquisition of all theoretical mass spectra (SWATH), in 
which data-independent acquisition is coupled with peptide spectral library 
match (Gillet et al., 2012). Per biopsy, 30 μg of peptides were used for 
SWATH measurement and 100 μg of peptides were used for library 
preparation.  For library generation, 100 μg of peptides from each of the 
biopsies were pooled and subjected to high-pH reverse phase fractionation 
by 5 injections of 200 μg on an Agilent 1260 Infinity HPLC.  The 36 collected 
fractions were subsequently pooled into 12 fractions by concatenation. 
 
SWATH analysis and library preparation.  Biopsies were analyzed on a 
Thermo Scientific QExactive Plus instrument coupled to an Easy nLC 1000 
capillary pump.  10 % of iRT peptide mix (HRM kit, Biognosys) was added to 
both SWATH and library samples prior to injection.  Proteome was analyzed 
by capillary LC-MS/MS using a PicoFrit separating column (0.075 mm × 38 
cm) (New Objective) packed with Reprosil C18 reverse-phase material (2.4 
μm particle size; Dr. Maisch).  For SWATH measurements, one Full MS-SIM 
scan at resolution 70.000 was followed by 40 mass windows of dynamic size 
ranging from 400 to 1600 m/z with 4 kDa overlap at resolution 17.500.  For 
library measurements, the mass spectrometer was operated in data-
dependent mode and the precursor scan was done at a 70,000 resolution. A 
top-20 method was run. 
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Data analysis (SWATH).  The library was generated with MaxQuant (version 
1.5.1.2) using the default settings except that the mass tolerance of the 
instrument was set to 10 ppm and the minimal ratio count for quantification 
was set to 1.  The Uniprot SwissProt database (17th August 2015) including 
the iRT fusion peptide was used for the searches.  The SWATH runs were 
analyzed with Spectronaut (version 9.0.11240.2) (Biognosys) with the default 
settings used.  
 
Human data sets (transcriptome).  Gene expression data from RNA 
sequencing was obtained from the Cancer Genome Atlas (TCGA) and 
Genotype-Tissue Expression (GTEx) projects (STAR Methods).  Tissue 
types are sorted by median expression.  To compare expression levels, we 
used the transcript per million unit (TPM), a measure of overall transcript 
abundance of genes. 
 
Lipid extraction protocols.  Lipid extraction was performed using a 
modified MTBE protocol. Briefly, for time-course lipidome analysis fresh liver 
samples from 4, 8, 12 and 20 (cancer tumors were obtained) week-old L-dKO 
and control mice (n=6 per time point) were used.  For assessment of 
mTORC2-regulated lipids, 20 week-old L-TriKO, L-dKO and control mice 
were used (n=4 per group).  To examine the in vivo effect of myriocin, 
lipidomics of liver samples from myriocin or the drug vehicle treated L-dKO 
(n=5 myriocin, n=6 vehicle) and control (n=5 myriocin, n=4 vehicle) mice 
were performed.  As described above, in all cases, tissues were immediately 
snap-frozen in liquid nitrogen.  Subsequently, tissues were pulverized into a 
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fine powder in an in-house-constructed metal mortar, pre-cooled on dry ice 
(‘cryogenic grinding’, as described above).  Of that, 30-35 mg ground liver 
tissue was weighted in a pre-chilled 2 mL Eppendorf Safe-Lock tube and 
resuspended in 100 μl H2O and transferred into a 2 mL Eppendorf tube.  
Then, 360 μl methanol was added and vortexed.  A mixture of lipid standards 
(see Key Resources Table) plus 50 μl 1.4 mm Zirconium glass beads (Bertin 
Technologies, France) were added and the pulverized tissue was 
homogenized using a Cryolysis System (Bertin Technologies, France) 
(program: 6200-3x45-045) cooled to 4 °C.  MTBE (1.2 mL) was then added 
and the sample was incubated for one hr at room temperature with a shaking 
(750 rpm).  Phase separation was induced by adding 200 μl H2O. After 10 
min of incubation at RT, the sample was centrifuged at 1000 x g for 10 min 
(RT).  The upper (organic) phase was transferred in a 13 mm screw cap 
glass tube and the lower phase was extracted with 400 μl artificial upper 
phase (MTBE/methanol/water (10:3:1.5, v/v)).  The two upper phases were 
combined and the total lipid extract was divided in 3 equal aliquots (one for 
phospholipids (TL), one for sterols (S) in 2 mL amber vials and one for 
sphingolipid (SL) detection in a 13 mm glass tube) and dried in a Centrivap at 
50°C or under a nitrogen flow.  The TL and S aliquots were ready to be 
analyzed by mass spectrometry and were kept at -80°C.  The SL aliquot was 
deacylated to eliminate phospholipids by methylamine treatment (Clarke 
method). 0.5 mL monomethylamine reagent (MeOH/H2O/n-
butanol/Methylamine solution (4:3:1:5 v/v) was added to the dried lipid, 
followed by sonication (5 min).  Samples were then mixed and incubated for 
one hr at 53°C and dried (as above).  The monomethylamine treated lipids 
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were desalted by n-butanol extraction.  300 μl H2O saturated n-butanol was 
added to the dried lipids.  The sample was vortexed, sonicated for 5 min and 
150 μl MS grade water was added.  The mixture was vortexed thoroughly 
and centrifuged at 3200 x g for 10 min.  The upper phase was transferred in 
a 2 mL amber vial.  The lower phase was extracted twice more with 300 μl 
H2O saturated n-butanol and the upper phases were combined and dried (as 
above). 
For analysis of human biopsy samples, lipids were extracted from the same 
lysates used for immunoblot analysis (described above).  Human biopsy 
lysates (60-80 μl) were extracted with MTBE/methanol.  The aliquots were 
dried, then treated with 2 mg of urease (Sigma, U4002, 50,000-100,000 
units/g) in 750 μl 20 mM ammonium acetate, pH 7-7.5 for 1.5 hr at 30 °C to 
remove the remaining urea that co-isolated with the lipid fraction.  After 
drying, the aliquot for sphingolipid analysis was treated with methylamine, 
dried, and both aliquots were desalted by butanol extraction. 
 
Phospholipid and sphingolipid detection on a triple quadrupole TSQ 
Vantage (ThermoFischer Scientific).  LC-MS or HPLC grade solvents were 
used and the samples were pipetted in a 96 well plate (final volume = 100 μl).  
Positive mode solvent: Chloroform/Methanol/Water (2:7:1 v/v) + 5mM 
Ammonium Acetate.  Negative mode solvent: Chloroform/Methanol (1:2 v/v) 
+ 5mM Ammonium Acetate.  The TL and SL aliquots were resuspended in 
250 μl Chloroform/methanol (1:1 v/v) and sonicated for 5 min.  The TL were 
diluted 1:50 in negative and positive mode solvents and the SL were diluted 
1:10 in positive mode solvent and infused onto the mass spectrometer.  
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Tandem mass spectrometry for the identification and quantification of 
phospho- and sphingolipid molecular species was performed using multiple 
reaction monitoring (MRM) with a TSQ Vantage Triple Stage Quadrupole 
Mass Spectrometer (Thermo Fisher Scientific) equipped with a robotic 
nanoflow ion source, Nanomate HD (Advion Biosciences, Ithaca, NY).  The 
collision energy was optimized for each lipid class.  The detection conditions 
for each lipid class are listed below.  Ceramide species were also quantified 
with a loss of water in the first quadrupole.  Each biological replicate was 
read in 2 technical replicates (TR).  Each TR comprised 3 measurements for 
each transition.  Lipid concentrations were calculated relative to the relevant 
internal standards and then normalized to the total phosphate content of 
each total lipid extract, as described in (Ding et al., 2013).  Data was then 
normalized to age-matched control. 
 
Determination of total phosphorus.  A standard curve was constructed 
using 0, 2, 5, 10 and 20 μl of 3 mM KH2PO4 brought to 20 μl with H2O. The 
dried total lipid extract was resuspended in 250 μl chloroform/methanol (1:1 
v/v) and 50 μl were placed into a 13 mm disposable pyrex tube.  The solvent 
was completely evaporated and 20 μl of water was added to each sample 20 
μl of water and 140 μl of 70 % perchloric acid was then added to all tubes.  
Tubes were heated at 180 °C for 1 hr in a fume hood and cooled at RT for 5 
min.  Then 800 μl of freshly prepared H2O/1.25 % NH4-Molybdate/1.66 % 
ascorbic acid (5:2:1 v/v) were added.  Tubes were heated at 100 °C for 5 min 
with a marble on each tube to prevent evaporation and were cooled to RT.  2 
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x 100 μl of each sample was then transferred into a 96-well microplate and 
the absorbance at 820 nm was measured. 
 
Metabolite extraction protocol.  Pulverized liver tissues were obtained as 
described above (5-8 mg) and resuspended in 200 μl extraction solvent 
(ethanol/water/diethylether/pyridine/ammonium hydroxide 4.2N 
(15:15:5:1:0.018)).  To that, a mixture of lipid standards (see Key Resources 
Table) and 50 μl 1.4 mm Zirconium glass beads (Bertin Technologies, 
France) were added.  The pulverized tissue was homogenized using a 
Cryolysis System (Bertin Technologies, France) (program: 6200-3x45-045) 
cooled at 4 °C.  The sample was incubated for 20 min on ice, centrifuged at 
21000 x g for 2 min and the supernatant was transferred to an Eppendorf 
tube.  The pellet was extracted a second time with 200 μl of extraction 
solvent.  The combined supernatants were centrifuged at 21000 x g for 5 min 
to remove remaining cell debris and split into two equal aliquots in 300 μl 
glass inserts.  The metabolite extract was dried in a Centrivap at 50 °C for 30 
min and then 60 °C for 2 hr. 
 
Derivatization of amino groups.  Dried lipid extract was resuspended in 10 
μl 0.1 % formic acid, 70 μl borate buffer (200 mM boric acid pH 8.8 (with 
NaOH), 10mM tris (2-carboxyethyl)phosphine (TCEP), 1 mM ascorbic acid, 
35.7 μM 13C15N-Valine (internal standard)).  The mixture was sonicated for 5 
min and 20 µl of 10mM AQC (2.85 mg/mL in acetonitrile) was added.  The 
sample was incubated for 15 min at 55 °C with shaking (750 rpm) followed by 
overnight incubation at 24 °C.  The quantification of the metabolites was 
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performed using multiple reaction monitoring (MRM) (See below) with a TSQ 
Vantage Triple Stage Quadrupole Mass Spectrometer (Thermo Fisher 
Scientific).  Area of each metabolite was normalized to the respective internal 
standard. 
 
LC-MS/MS-metabolomics.  After incubation, the sample was centrifuged as 
above and the supernatant transferred in a new insert.  10 μl were loaded 
onto a NUCLEOSHELL RP 18 (Particle size: 2.7 μm, length: 100 mm, 
Diameter: 2 mm) (MACHEREY-NAGEL) and a gradient (see below) was 
applied:  solvent A: milliQ water + 0.1 % formic acid, solvent B: isopropanol + 
0.1 % formic acid, at a flow of 300 μl/min. 
Detection of Lipids by MS/MS (related to lipidome analyses) 
Lipid Class Standard Polarity Mode m/z ion CE 
Phosphatidylcholine [M+H]+ PC31:1 + Product ion 184.07 30 
Phosphatidylethanolamine 
[M+H]+ PE31:1 + Neutral ion loss 141.02 
20 
Phosphatidylinositol [M-H]- PI31:1 - Product ion 241.01 44 
Phosphatidylserine [M-H]- PS31:1 - Neutral ion loss 87.03 23 
Cardiolipin [M-2H]2- CL56:0 - Product ion acyl chain 32 
Ceramide [M+H]+ C17Cer + Product ion 264.30 25 
Dihydroceramide [M+H]+ C17Cer + Product ion 266.40 25 
Hexacylceramide [M+H]+ C8GC + Product ion 264.30 30 
Hexacyldihydroceramide 
[M+H]+ C8GC + 
Product ion 266.40 30 
Sphingomyelin [M+H]+ C12SM + Product ion 184.07 26 
 
MRM list for detection of sphingoid bases (metabolomics) 
Q1 Q3 CE 
456.322 171.055 20 
456.358 171.055 20 
470.338 171.055 20 
472.353 171.055 20 
536.501 171.055 30 
538.304 171.055 30 
550.304 171.055 30 
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552.32 171.055 30 
 
Gradient Nucleoshell RP 18 column 
N° Time A% B% C% D% µl/min 
0 0 99 1 0 0 300 
1 12 90 10 0 0 300 
2 14.5 60 40 0 0 300 
3 18.5 20 80 0 0 300 
4 20 0 100 0 0 300 
5 22.5 0 100 0 0 300 
6 24 99 99 0 0 300 
7 30 99 99 0 0 300 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Statistical analysis – mouse phosphoproteome and proteome:  The data 
was analyzed with the Perseus software, version 1.4.0.2 (Tyanova et al., 
2016).  For mouse data, volcano plots based on ANOVA two sample t-test 
were performed.  S0 and FDR were set to 0.5 and 5 % respectively and 
number of randomizations were kept at 250.  For the hierarchical clustering, 
only proteins that were significantly deregulated in at least one time point (4, 
8 or 12 weeks) were included.  Normalization was performed using Z-scoring 
within a given time point.  Finally, unsupervised hierarchical clustering was 
performed, the distance was set to Pearson, the linkage to average, and the 
maximal numbers of clusters to 300 (Tyanova et al., 2016). In data obtained 
from tumors (20 weeks), up- or down regulated proteins (Figure 1C) were 
included if detected in at least 11 tumors (out of 12 tumors measured), and 
deregulated in at least 75% of total detections.  Binarization of the data was 
done based on the volcano plot analysis. Additionally, we included 
data exceeding a threshold for Log2 fold change of +/-1. ‘Black and white’ 
cases (i.e., proteins that were detected either in mutant or in control, but not 
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in both) were included only if the detection was true in 3/3 control runs and 
0/3 tumor runs and vice versa. 
 
Human biopsies proteome – the data was analyzed using Perseus as 
described above.  Volcano plots based on ANOVA two sample t-test were 
performed, S0 and FDR were set to 0.1 and 2% respectively, number of 
randomizations we kept at 250.  Binarization of the data was done using 
thresholds for Log2 fold change of +/- 0.7 if the volcano plot analysis returned 
a significant change otherwise we used a threshold for Log2 fold change of 
+/-1. ‘Black and white’ situations were also included if the detection was true 
in 3/3 control runs and 0/3 tumor runs and vice versa.  Unsupervised 
hierarchical clustering was performed after Log2 ratios of tumor versus non-
tumor data were normalized using z-scoring.  The distance was set to 
Pearsons or Spearmans, the linkage to average and k-means algorithm was 
disabled (Tyanova et al., 2016). 
 
Statistical analysis – lipidome:  To generate categories of minor, medium 
or major species, we used 68 biological replicas from liver samples of wild 
type mice (all were sacrificed at 6:00am).  Within individual lipid species we 
defined the categories based on median raw abundances.  The data was 
analyzed with the Perseus software, version 1.4.0.2.  For the volcano plots, 
an ANOVA two-sample t test was performed, adjusting S0 to 0.1, number of 
randomizations to 250, and FDR to 5 %.  For the heat maps, only lipid 
species that were significantly deregulated in at least one time point were 
included.  Z-scoring was performed with grouping within same time points.  
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Finally, for unsupervised hierarchical clustering, the distance was set to 
Euclidian, the linkage to average, and the maximal numbers of clusters to 
300. 
Immunoblots for AKT2-pS473 and AKT were quantified using Fiji.  
Sample size was chosen according to our previous studies and published 
reports in which similar experimental procedures were described.  No 
blinding of investigators was done.  All data are shown as mean ± SEM.  
Sample n numbers are indicated in figure legends.  For mouse experiments, 
n number represents number of animals used in a group.  For cell culture 
experiments, n number indicates number of independent experiments.  Fold 
changes in Figure S6E were calculated from 3 independent experiments.  
To statistically determine the significance between two groups, 
unpaired Student’s t test was performed, unless otherwise indicated. 
 
Data analysis.  Statistical analyses and data plotting were performed using 
Prism Graph Pad 6.0.  Unless mentioned otherwise, statistical significance 
was defined as <0.05.  An unpaired t-test assuming Gaussian distribution 
was used to compare between two groups.  Kaplan-Meier method was used 
for survival analysis.  Data represent mean ± SEM. 
 
List of Supplemental Tables 
Table S1. Related to Figure 1. Enrichment analyses by Pathway Maps. 
Table S2. Related to Figure 1. Proteome, phosphoproteome and RNAseq 
from young (4, 8 and 12 week-old) and 20 week-old mice (HCCs). 
 54 
Table S3. Related to Figure 3. Longitudinal lipidomic analyses. 
Table S4. Related to Figure 4. Myriocin lipidomics analyses. 
Table S5. Related to Figure 7. mTORC2-regulated lipid species - lipid 
enrichment analysis. 
Table S6. Related to Figure 8. Human patients information. 
Table S7. Related to Figure 8. Lipogenesis biosynthetic enzymes in patient 
HCCs. 
Table S8. Related to STAR methods. Primer sequences. 
 
